MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Form 8-K — Nov 4, 2026
Maravai LifeSciences (NASDAQ: MRVI) reported Q3 2026 revenue of $45.9 million, up 10.1% year-over-year, with TriLink up 11.8% and Cygnus up 7.5%. mRNA revenue grew 28% YoY. The company swung to positive Adjusted EBITDA of $5.8 million versus $(10.8) million a year ago, though it still posted a GAAP net loss of $(24.0) million, or $(0.09) per Class A share. Four Discovery mRNA customers transitioned to clinical-stage GMP during the quarter.
Key figures
- Revenue
- 45900000
- Guidance
- Full year 2026 revenue raised to $212.0M-$216.0M (from $205.0M-$215.0M); Adjusted EBITDA raised to $40.0M-$42.0M (from $33.0M-$35.0M)
- Revenue Yoy
- 10.1%
- Cygnus yoy pct
- 7.5%
- Trilink yoy pct
- 11.8%
- Cygnus q3 revenue
- 17501000
- Trilink q3 revenue
- 28350000
- Adjusted EBITDA q3 2026
- 5820000
- M RNA revenue growth yoy
- 28%
- Covid clean Cap revenue 9m
- 14300000
- Adjusted EBITDA nine months
- 34821000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.